The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

Organon (OGN) stock on watch as FDA delays a potential label expansion for its VTAMA cream, impacting 2025 EBITDA margin and ...

Thankfully, many skincare brands have taken into account the large segment of the population who struggle with sensitive skin ...

Learn about the benefits and risks of probiotic supplements and how to choose the best one for your health goals.

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Background: Finding alternative hair dyes for individuals allergic to para-phenylenediamine (PPD) has been difficult. Newer permanent and demipermanent hair dyes that have replaced PPD with para ...

Q3 2024 Earnings Call Transcript November 3, 2024 Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter ...

Bionoid Pharma, Inc. ("BINP") has outlined a five-year roadmap focused on expanding revenue streams and brand presence through a targeted acquisition strategy and a shift toward long-term ...